Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

BACKGROUNDS/AIM: Sodium glucose co-transporter 2 inhibitors promote osmotic/natriuretic diuresis and reduce excess fluid volume, and this improves cardiovascular outcomes, including hospitalization for heart failure. We sought to assess the effect of empagliflozin on estimated fluid volumes in patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Tanaka, Atsushi, Shimabukuro, Michio, Teragawa, Hiroki, Okada, Yosuke, Takamura, Toshinari, Taguchi, Isao, Toyoda, Shigeru, Tomiyama, Hirofumi, Ueda, Shinichiro, Higashi, Yukihito, Node, Koichi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237440/
https://ncbi.nlm.nih.gov/pubmed/34183012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01295-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados